Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized placebo-controlled study of abrocitinib oral suspension in children with moderate-to-severe atopic dermatitis
jRCT2071250011Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Jul 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing Abrocitinib with Placebo (2 arms). Primary endpoints: Validated Investigator's Global Assessment response at Week 12 and EASI-75 response at Week 12. Started Jul 2025; status: active, not recruiting.
02
Drugs
abrocitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2071250011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250011.